Scienture (NASDAQ:SCNX) Stock Rating Lowered by Wall Street Zen

Scienture (NASDAQ:SCNX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Scienture in a research note on Monday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Scienture presently has a consensus rating of “Sell”.

Scienture Stock Up 14.5%

NASDAQ SCNX opened at $0.57 on Friday. The firm has a market cap of $23.18 million, a P/E ratio of -0.57 and a beta of 2.95. Scienture has a 52-week low of $0.46 and a 52-week high of $8.15. The business’s 50-day moving average price is $0.71 and its 200 day moving average price is $1.08.

Scienture (NASDAQ:SCNX) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.19) EPS for the quarter. Scienture had a negative net margin of 10,364.22% and a negative return on equity of 25.18%. The company had revenue of $0.59 million for the quarter.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.